- Home
- DLPN vs NXTC Comparison
DLPN vs NXTC Comparison
Compare DLPN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- NXTC
- Stock Information
- Founded
- DLPN 1996
- NXTC 2015
- Country
- DLPN United States
- NXTC United States
- Employees
- DLPN N/A
- NXTC N/A
- Industry
- DLPN Other Consumer Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- DLPN Consumer Discretionary
- NXTC Health Care
- Exchange
- DLPN Nasdaq
- NXTC Nasdaq
- Market Cap
- DLPN 12.6M
- NXTC 13.0M
- IPO Year
- DLPN N/A
- NXTC 2019
- Fundamental
- Price
- DLPN $1.19
- NXTC $5.44
- Analyst Decision
- DLPN Strong Buy
- NXTC Strong Buy
- Analyst Count
- DLPN 1
- NXTC 2
- Target Price
- DLPN $5.00
- NXTC $25.50
- AVG Volume (30 Days)
- DLPN 580.9K
- NXTC 16.8K
- Earning Date
- DLPN 08-13-2025
- NXTC 11-06-2025
- Dividend Yield
- DLPN N/A
- NXTC N/A
- EPS Growth
- DLPN N/A
- NXTC N/A
- EPS
- DLPN N/A
- NXTC N/A
- Revenue
- DLPN $51,257,243.00
- NXTC N/A
- Revenue This Year
- DLPN $9.05
- NXTC N/A
- Revenue Next Year
- DLPN $15.42
- NXTC N/A
- P/E Ratio
- DLPN N/A
- NXTC N/A
- Revenue Growth
- DLPN 4.84
- NXTC N/A
- 52 Week Low
- DLPN $0.75
- NXTC $2.69
- 52 Week High
- DLPN $1.78
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- DLPN 51.86
- NXTC 59.42
- Support Level
- DLPN $1.14
- NXTC $4.77
- Resistance Level
- DLPN $1.21
- NXTC $5.15
- Average True Range (ATR)
- DLPN 0.07
- NXTC 0.22
- MACD
- DLPN 0.00
- NXTC 0.05
- Stochastic Oscillator
- DLPN 77.27
- NXTC 93.06
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.